Zhuravleva M V, Prokofiev A B, Arkhipov V V, Serebrova S Yu, Gorodetskay G I, Demidova O A
Research center for examination of medical devices, Moscow, Russia.
Sechenov First Moscow state medical University (Sechenov University), Moscow, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(3):92-96. doi: 10.17116/jnevro202012003192.
The analysis of the clinical efficacy and safety of ethylmethylhydroxypyridine succinate (mexidol) in the complex of rehabilitation measures in patients after ischemic stroke (IS) shows that course treatment with mexidol improves the recovery of neurological functions, decreases neurological deficit, cognitive disorders, including memory impairment, and manifestations of asthenic syndrome, increases the level of social adaptation and improves the psycho-emotional state of patients, reduces spasticity, increases motor and speech activity, praxis, reliably eliminates the ignoring syndrome. There is a decrease in the level of total cholesterol and low-density b-lipoproteins in the blood, and decrease in the severity of hypercoagulation. The results of the studies have convincingly shown the efficacy of mexidol at all stages of rehabilitation treatment of patients with IS.
对琥珀酸乙甲基羟基吡啶(美西多芬)在缺血性中风(IS)患者康复措施综合治疗中的临床疗效和安全性分析表明,美西多芬疗程治疗可改善神经功能恢复,减少神经功能缺损、认知障碍(包括记忆损害)和虚弱综合征表现,提高社会适应水平,改善患者心理情绪状态,减轻痉挛,增加运动和言语活动、实践能力,可靠消除忽视综合征。血液中总胆固醇和低密度β脂蛋白水平降低,高凝严重程度减轻。研究结果令人信服地表明美西多芬在IS患者康复治疗各阶段均有效。